Brief: Hls Therapeutics Provides Investor Update On The Canadian Launch Of Vascepa®
28/01/2020 11:38
Jan 28 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS PROVIDES INVESTOR UPDATE ON THE CANADIAN
LAUNCH
OF VASCEPA® (ICOSAPENT ETHYL)
* HLS THERAPEUTICS INC - VASCEPA TO BE AVAILABLE ON OR ABOUT
FEBRUARY 18, 2020, SUPPORTED BY A NATIONAL CARDIOVASCULAR
SALESFORCE
* HLS THERAPEUTICS INC - VASCEPA IS SUPPORTED BY DATA FROM
REDUCE-IT TRIAL
Source text for Eikon: ID:nCNWrTCvMa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease